RxDoctor Payments Data

Horacio Hidalgo, MD

Family Medicine · Levittown, PANPI 1356309462

Payments from drug & device makers

$15,002in general payments, 2019–2025

Across 578 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$3K
  • AbbVie$2K
  • Merck$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Pfizer$823
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$11,066100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,002 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$112,727
Medicare patients
222
Services billed
1,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide137$152,975
EliquisApixaban77$73,286
FarxigaDapagliflozin Propanediol48$60,990
JanuviaSitagliptin Phosphate41$49,905
JardianceEmpagliflozin30$43,362
MounjaroTirzepatide37$37,553
WegovySemaglutide22$28,479
XareltoRivaroxaban16$21,658
Breo ElliptaFluticasone/Vilanterol31$16,636
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,328
TrulicityDulaglutide15$14,214
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$9,339
Tegretol XrCarbamazepine11$9,179
MyrbetriqMirabegron15$9,039
Atorvastatin Calcium597$8,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,478$181,454159 claims
PfizerEliquis$823$73,28677 claims
AstraZenecaFarxiga, Symbicort$1,038$65,76063 claims
Lilly USA, LLCMounjaro, Trulicity$760$51,76852 claims
MerckJanuvia$1,612$49,90541 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$300$44,89180 claims
Boehringer IngelheimJardiance$289$43,36230 claims
Johnson & JohnsonXarelto$282$21,65816 claims
Astellas Pharma US IncMyrbetriq$184$9,03915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Levittown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →